Search

• GSK announces regulatory submissions for subcutaneous formulation of Benlysta® (belimumab) for patients with systemic lupus disease

  Media

  It has filed regulatory submissions in the US and Europe for Benlysta® (belimumab) for approval.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submissions-for-subcutaneous-formulation-of-benlysta-belimumab-for-patients-with-systemic-lupus-disease/

  First published: 23 September 2016

• ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV

  Media

  The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral tablets.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/

  First published: 10 June 2016

• GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator

  Media

  Submission included data from trials addressing clinical manifestations of myelofibrosis - splenomegaly, constitutional symptoms and anaemia

  https://www.gsk.com/en-gb/media/press-releases/gsk-regulatory-submission-for-momelotinib-for-the-treatment-of-myelofibrosis-accepted-for-review-by-japanese-regulator/

  First published: 11 September 2023

• New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade

  Media

  End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination.

  https://www.gsk.com/en-gb/media/press-releases/new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles-in-adults-aged-50-and-over-for-more-than-a-decade/

  First published: 17 April 2024

• 

  Targeting treatable traits in asthma and other respiratory conditions

  Behind the science magazine

  Targeting certain treatable traits an individual may exhibit could have a significant impact on their quality of life

  https://www.gsk.com/en-gb/behind-the-science-magazine/targeting-treatable-traits-in-asthma-and-other-respiratory-conditions/

  First published: 06 April 2022

• 

  Using new science to get ahead of myelofibrosis - a rare blood cancer

  Behind the science magazine

  Myelofibrosis is a serious blood cancer that involves the build-up of excessive scar tissue in the bone marrow.

  https://www.gsk.com/en-gb/behind-the-science-magazine/using-new-science-to-get-ahead-of-blood-cancer-myelofibrosis/

  First published: 18 November 2022

• 

  ‘Local innovation is vital to our mission to ensure no child is left to suffer from a vaccine preventable disease’

  Behind the science magazine

  Save the Children are looking for local innovators in Ethiopia and Nigeria to help come up with new ways to get vaccines to children in need

  https://www.gsk.com/en-gb/behind-the-science-magazine/child-immunisation-accelerator-comment/

  First published: 23 April 2024

• Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD

  Media

  Acceleration of filing of US New Drug Application now expected by end of 2016

  https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-us-filing-plans-for-closed-triple-combination-therapy-ffumecvi-in-patients-with-copd/

  First published: 02 June 2016

• GSK becomes partner in new global fund to accelerate dementia research

  Media

  Company makes $25m (approx £17m) investment in first-of-its-kind venture capital fund focused on dementia

  https://www.gsk.com/en-gb/media/press-releases/gsk-becomes-partner-in-new-global-fund-to-accelerate-dementia-research/

  First published: 17 March 2015

• GlaxoSmithKline plc announces Board and Committee changes

  Media

  GSK today announces that Manvinder Singh (Vindi) Banga will join GSK’s Board as a Non-Executive Director on 1 September 2015.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-board-and-committee-changes/

  First published: 07 May 2015